NCPE - National Centre for Pharmacoeconomics’ Post

✳ We are thrilled to share our exclusive interview with the amazing Professor Don Ingber, founding director of the Wyss Institute at Harvard University and pioneer of the organs-on-chip #OoC technology. 🔵 Among the highlights of the interview, Prof. Ingber discussed the success of Emulate, Inc.'s Liver-chips in predicting drug-induced liver injury (#DILI), bone marrow chips and their potential to assess drug side effects and contribute to personalized medicine and the reasons that make #OoC technology a “revolutionary approach to better understand human diseases and assess drug toxicity.” 🔴 The researcher also emphasised the need for #robust methods and the necessity to #harmonize globally the quality of qualification of techniques and validation of criteria. He also mentioned the current obstacles to the acceptance of these new methods and social barriers, notably in regulatory toxicology. 🌟 The interview reflects both the positive and constructive vision of the researcher, and his enthusiasm regarding the evolution of biomedical research and the potential of OoC technology. Read the full interview EN➡️https://lnkd.in/eedsDxFF FR➡️https://lnkd.in/ey6A55p3 Subscribe to our quarterly review (in french) https://lnkd.in/e28sU-9j

🧪 Trailblazing biomimicry: Bailey Richardson and a new era of medical applications 🧪 At the intersection of innovation and medical science, PhD student Bailey Richardson in the QUT Centre for Materials Science is pioneering a future where biomimetic chemistry transforms healthcare. Bailey's work, focusing on peptide self-assembly controlled photoreactivity, heralds a new era of medical applications, from targeted drug delivery to precision diagnostics. Read the latest #COSMOS article to discover what fuels Bailey's passion for biomimetic chemistry: https://bit.ly/3ISIIRc

🎉 Exciting news for Biosensing Instrument Inc! They have been awarded $295,561 by the U.S. Department of Health and Human Services (HHS)  , specifically the National Institutes of Health and the National Institute of General Medical Sciences. This grant will support their groundbreaking work in developing Plasmonic Scattering Microscopy (PSM) for high-throughput, in-situ quantification of molecular binding kinetics on single cells. This technology is set to revolutionize biomarker discovery and drug development by enabling real-time functional studies of drug interactions with cell membrane receptors in their native environments. #SBIR #STTR #Innovation #Biotech 🔬 The project aims to create a commercial prototype of a multi-functional PSM instrument that can perform both PSM and fluorescence imaging. This will address the significant unmet need for acquiring more native, biorelevant data earlier in the drug development process, thereby mitigating costly missteps and false leads. The research type is a project grant, and the award will last for 12 months, starting on September 1, 2024, and ending on August 30, 2025. #DrugDevelopment #BiomarkerDiscovery #HealthcareInnovation

Another successful AACR in the books for Teiko! Great energy from scientists, clinicians, advocates, and patients, with tons of promising science on display. It's clear that understanding the fuller picture is key in drug development. Pharma companies are increasingly interested in diving deeper into the mechanisms behind their drugs, particularly the biological changes and the unique dynamics of the immune system, that drive treatment response in patients. We're seeing a surge in interest for high-dimensional approaches like mass cytometry, full spectral flow cytometry, and spatial proteomics of blood and tumor samples. It's not one or the other, but a suite of complementary and validating assays that provide valuable insights to accelerate drug development, approval, and treatment access to patients. 💪 #AACR #AACR24 #Science #DrugDiscovery #MassCytometry #FlowCytometry #Innovation #PrecisionMedicine #Immunotherapy

Earlier this week, our Executive Director, Nick Lench, participated in a panel discussion at the 24th Bio€quity Europe Conference in San Sebastián. Chaired by Selina Koch, PhD, Nick and fellow panellists Rowan Gardner and Emmanuelle Astoul discussed how to leverage Europe's extensive biomedical data resources to enhance drug discovery and development. "For rare diseases in particular, the UK and Europe have extensive genomic and clinical data that can be mined to validate targets, stratify patients and develop precision therapies." 🤝 Building collaborations and partnerships and the sharing of high-quality data sets are essential to drive translational research for the benefit of patients. BioCentury Inc. PrecisionLife Wellcome Sanger Institute #NATA #Research #Science #Innovation #AdvancedTherapies #RNATherapeutics #therapeutics #drugdiscovery #biotech #collaboration #partnership #TranslationalResearch #RareDiseases #PrecisionTherapy #PersonalisedTherapy

#Journal_Club Session 6 The Journal Club will be held on Tuesday February 8, 2022, from 7:00 PM to 8:00 PM. In this session, we will discuss the article titled: "An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19" Lecturer: Dr. Elaheh Kashani-Amin (https://lnkd.in/gH_tXDf7) PhD, Molecular Medicine, Protein Molecular Modeling and Computer-aided Drug Design These are the highlights of this review article: 1) Structure-Based Drug Design:  - Molecular docking tools for protein-ligand interaction studies - A summary of commonly used molecular dynamic (MD) simulation software 2) Ligand-Based Drug Design - A list of pharmacophore modelling tools - List of programs available for calculating molecular descriptors for building QSAR models 3) Case Study of COVID-19 4) Strengths and Challenges of CADD in COVID-19 Research The sessions are free of charge. To register and receive the group link, please contact us via email: Email: elahehkashaniamin@gmail.com Social Media Links: - Telegram: @molecular_modeling - Instagram: @go_molecular_modeling #drugdesign #computationaldesign #molecularmodeling #computationaldesign #drugdiscovery #drugdevelopment #pharmacophore #covid19 #CADD 

One small detail makes all the difference between a reproducible experiment and one that is not, according to Robert Campbell, Ph.D., editor-in-chief of SLAS Discovery: Advancing the Science of Drug Discovery. Campbell comments in a recent SLAS Electronic Laboratory Neighborhood article that reproducibility is rooted in appropriate experimental design, well-described methods, and inclusion of all pertinent details – particularly when scientists enter the publishing process. In the same article, Kenda LJ Evans, Ph.D., of Agilent Technologies (Santa Clara, CA, USA), and co-chair for the SLAS Screen Design and Assay Technology Topical Interest Group (TIG), comments: “The challenges of reproducibility are not going to go away. We need it when we’re making go/no-go decisions. If you don’t have good reproducibility, it’s hard to know what’s a true result and what’s a false-positive. I think that talking about reproducibility and finding better ways of achieving it in our assays is crucial to drug discovery and research.” Read what other subject matter experts have to say in the article: https://lnkd.in/gNEspcne.

The DDC will be happening in Barcelona for the first time, Dec3-5. One of the best drug discovery conferences crossing the Atlantic and landing in Europe. Do not miss this chance to listen to great talks, exchange and network. Our CSO Victor Guallar, also group leader of the EAPM lab at Barcelona Supercomputing Center, will be one of the speakers. He will discuss the potential of AI for #polypharmacology, and how we are exploring this path at Nostrum Biodiscovery. Details of the talk: Thu 5 Dec 08:30 Can AI Give Us the Dreamed-of True Polypharmacology Solutions? Everybody agrees that finding small molecules that can bind specifically to selected 2-3 targets (not to hundreds of anti-targets) is the ultimate drug design goal for complex diseases. While this has been limited to serendipity or to some flavour of (mostly inefficient) merging/fusing/linking approach, now AI is allowing us to dream of finding true small molecule polypharmacology. We will introduce our efforts in this line and recent implementation studies, demonstrating that such a dream is possible today.

In this short movie, you can see the mechanical effect/ stress on the cellular and the intracellular levels in diagnostic and especially in treatment applications. I invite you to watch. 🎤Presenter: Professor Ayache Bouakaz ⏱️In Scientific session Non-ionising radiation: Ultrasound-mediated drug delivery Title: Recent advances in ultrasound-mediated drug delivery: Insights from preclinical and clinical trials. #UltrasoundMechanics #CellularStress #IntracellularEffects #DiagnosticApplications #TreatmentApplications #ScientificSession #NonIonisingRadiation #UltrasoundDrugDelivery #ClinicalTrials #PreclinicalResearch

Join us today in #Session4 at #ICML2024 to talk about antibody design and humanness prediction. In collaboration with University of Cambridge, we show how ML models can help in predicting immunogenic responses in antibody candidates, improving accuracy and reducing development costs. Paper: Improving antibody humanness prediction using patent data Authors: Talip Uçar, Aubin Ramon, Dino Oglic, Rebecca Croasdale-Wood, Tom Diethe, Pietro Sormanni